Idexx Laboratories (IDXX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Block from Stifel Nicolaus maintained a Hold rating on the stock and has a $460.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jonathan Block has given his Hold rating due to a combination of factors that present a mixed outlook for Idexx Laboratories. On the positive side, the company has shown promising developments with the rollout of its inVue systems and the initial launch of its Cancer Dx test, both of which have been well-received in the market. Additionally, Idexx’s recurring revenue growth in the Companion Animal Group Diagnostics (CAG Dx) segment was in line with expectations, and the company managed to deliver an earnings per share (EPS) beat, driven by gross margin improvements.
However, there are concerns that temper the overall outlook. Clinical visit growth has been under pressure, showing a year-over-year decline, which could impact future revenue growth. Furthermore, the worldwide and U.S. “IDEXX Premium” metrics have fallen below previous estimates, indicating potential challenges in maintaining pricing power and market share. These mixed signals contribute to the Hold rating, as the positives are balanced by uncertainties and pressures that could affect the company’s performance moving forward.
In another report released on April 21, Bank of America Securities also reiterated a Hold rating on the stock with a $475.00 price target.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IDXX in relation to earlier this year.